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Progression and severity of type 1 diabetes is dependent upon inflammatory induction of
nitric oxide production and consequent pancreatic β-cell damage. Glucocorticoids (GCs) are
highly effective anti-inflammatory agents but have been precluded in type 1 diabetes and in
islet transplantation protocols because they exacerbated insulin resistance and suppressed
β-cell insulin secretion at the high-doses employed clinically. In contrast, physiological-range
elevation of GC action within β-cells ameliorated lipotoxic β-cell failure in transgenic mice
overexpressing the intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (MIP-
HSD1tg/+ mice). Here, we tested the hypothesis that elevated β-cell 11beta-HSD1 protects
against the β-cell destruction elicited by streptozotocin (STZ), a toxin that dose-dependently
mimics aspects of inflammatory and autoimmune tg/β-cell destruction. MIP-HSD1 + mice
exhibited an episodic protection from the severe hyperglycemia caused by a single high
dose of STZ associated with higher and sustained β-cell survival, maintained β-cell replica-
tive potential, higher plasma and islet insulin levels, reduced inflammatory macrophage
infiltration and increased anti-inflammatory T regulatory cell content. MIP-HSD1tg/+ mice
also completely resisted mild hyperglycemia and insulitis induced by multiple low-dose
STZ administration. In vitro, MIP-HSD1tg/+ islets exhibited attenuated STZ-induced nitric
oxide production, an effect reversed with a specific 11beta-HSD1 inhibitor. GC regenera-
tion selectively within β-cells protects against inflammatory β-cell destruction, suggesting
therapeutic targeting of 11beta-HSD1 may ameliorate processes that exacerbate type 1
diabetes and that hinder islet transplantation.
Keywords: glucocorticoids, 11beta-hydrosteroid dehydrogenase type 1, type 1 diabetes, inflammation, beta-cells,
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INTRODUCTION
Type 1 diabetes is a chronic disease characterized by inflammatory
β-cell destruction secondary to an initial autoimmune targeting
of the islets (1). Inflammatory macrophages are key to the devel-
opment and maintenance of islet damage (2). Pro-inflammatory
cytokines derived from macrophages and damaged β-cells further
suppress β-cell function in part through induction of nitric oxide
production (3, 4). As type 1 diabetes progresses, pro-inflammatory
cytokines inhibit β-cell regeneration, stimulate peripheral insulin
resistance and maintain insulitis (1).
Glucocorticoids (GCs) are used clinically due to their potent
anti-inflammatory and immunosuppressive effects (5) but were
excluded as a treatment for type 1 diabetes and in transplant pro-
tocols (6) because they promoted peripheral insulin resistance
and suppressed β-cell function at the high-doses employed (7–
9). However, the prevailing dogma that GC action on β-cells
is purely deleterious has been increasingly challenged (10–14).
Exposure of normal mouse islets to GCs can improve aspects
of secretory function through suppression of inflammatory sig-
naling (10). Moreover, pre-treatment of islets with GCs (11) or
localized exposure of transplanted islets to GCs contained within
their surrounding implant matrix (12) has shown improved effi-
cacy and graft survival. Crucially, transgenic mice with mod-
est β-cell-specific elevation of the intracellular GC regenerating
enzyme 11β-hydroxysteroid dehydrogenase (HSD11b1; 11beta-
HSD1; MIP-HSD1 mice) exhibited protection from lipotoxic β-
cell failure in vivo as a result of increased islet number, arising
from a post-developmental effect, and function, due to enhanced
secretory capacity and cell survival signaling (14).
The beneficial effects of β-cell-specific 11beta-HSD1 elevation
(14) were manifest in a chronic high-fat feeding obesity model.
Although obesity is associated with a low-grade inflammation of
the islets (15), the protective mechanisms found in MIP-HSD1
islets were not obviously anti-inflammatory (14). Therefore, the
impact of intra-β-cell GC regeneration on the processes of cellular
damage occurring in profoundly inflammatory contexts relevant
to type 1 diabetes remains unknown. To address this we tested the
hypothesis that elevated β-cell 11beta-HSD1 protects against the
profound β-cell destruction or inflammatory insulitis driven by
distinct doses of the β-cell toxin streptozotocin (STZ).
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MATERIALS AND METHODS
ANIMALS
All experiments conformed to local ethical guidelines of the Uni-
versity of Edinburgh and the UK Home Office Animals (Scien-
tific Procedures) Act (1986). Male MIP-HSD1tg/+ and C57BLKS/J
(KsJ) littermate control mice (14) were housed in standard condi-
tions on a 12 h light/dark cycle and fed standard rodent chow (Spe-
cial Diet Services, Edinburgh, UK). Age matched 10–12-week-old
male mice were used for all the experiments.
STREPTOZOTOCIN TREATMENTS
Mice were injected intraperitoneally with a single bolus of
STZ (180 mg/kg/body weight) or for five consecutive days with
40 mg/kg/body weight STZ dissolved in 10 mmol/l sodium citrate
(pH 4.5) or vehicle. Blood glucose was measured (OneTouch Ultra,
Johnson and Johnson, Bucks, UK) from a tail venesection. Mice
were sacrificed at 3 and 10 days (single dose) or 15 days (multi-
ple dose) after injection. Insulin was measured by ELISA (Crystal
Chem, Downers Grove, IL, USA).
IMMUNOHISTOCHEMISTRY
Pancreata were fixed in 4% paraformaldehyde, paraffin embed-
ded, sectioned (4µm), and immunostained with guinea pig
anti-insulin (1:300) (AbCam, Cambridge, UK), rabbit anti-Mac-
2 (1:150) (Cedarline, ON, Canada), rabbit anti-FOXP3 (1:150)
(eBioscence, Hatfield, UK), rabbit anti-NEUROG3 (1:1000), and
rabbit anti-SOX9 (1:8000) (Millipore Corporation, Bellirica, MA,
USA). For chromogen labeling with diaminobenzidine (DAB)
(Dakocytomation, Carpinteria, CA, USA) biotinylated anti-guinea
pig and anti-rabbit (AbCam) secondary antibodies were used.
Image and quantification of positive cells in islet areas were carried
out using KS300 software (3.0 CarlZeiss Vision, GmBH) or com-
puterized image analysis (MCID Basic 7.0 software) for analysis of
the whole sections. For immunofluorescence, sections were incu-
bated with rabbit anti-ki67 (1:3000, Dakocytomation) then goat
anti-rabbit peroxidase (Abcam) followed by Tyramide green 488
(Perkin Elmer, Cambridge, UK) then incubated with rabbit anti-
PDX1 (1:1000, Millipore). After antigen retrieval, sections were
incubated with goat anti-rabbit Alexa Fluor 546 (1:200, Molecular
probes,Paisley,UK) and DAPI (1:1000,Sigma Aldrich,Dorset,UK)
and visualized using a Leica fluorescence microscope. Quantifica-
tion for PDX1 and Ki67 was performed using Image J software
(http://www.ncbi.nlm.nih.gov).
ISLET ISOLATION AND PREPARATION
Pancreata were digested with collagenase XI (Sigma Aldrich) and
islets were hand-picked under a stereomicroscope in Hank’s Bal-
anced Salt Solution, 10% FBS (Lonza, Berkshire, UK). Batches
of 80 islets were incubated in RPMI-1640 (Gibco, Life Tech-
nologies, Paisley, UK), 10% FBS, 6.1 mmol/l d-glucose, 2 nmol/l
11-dehydrocorticosterone with or without 10 mmol/l STZ diluted
in sodium citrate 10 mmol/l and with or without L-NAME (Sigma)
5 mmol/l for 72 h on 8µm inserts (Millipore). Pictures of the islets
were taken using a Zeiss microscope and media were collected for
measurement of nitric oxide.
NITRIC OXIDE (NO) PRODUCTION
Total NO in the media was assayed as nitrite, the stable breakdown
product of NO, using a Sievers chemiluminescence analyzer
(Analytix, Sunderland, UK). Islets were homogenized in lysis
buffer as described in (14) and protein content evaluated by Biorad
assay (BioRad Laboratories, Hercules, CA, USA).
STATISTICS
Data are expressed as mean± SEM and were analyzed using
one-way ANOVA (Newman–Keuls post hoc test).
RESULTS
MIP-HSD1tg/+ MICE RESIST HIGH-DOSE STZ-INDUCED
HYPERGLYCEMIA
We began by administering a high-dose of STZ (180 mg/kg body
weight) known to completely ablate β-cell function (16). High-
dose STZ caused marked and comparable hyperglycemia by 2 days
in MIP-HSD1tg/+ and control non-transgenic littermates (KsJ),
indicating comparable ablation of β-cell function. However, after
day 3, during the inflammatory-response phase of islet destruc-
tion, MIP-HSD1tg/+ mice began to exhibit episodic phases of sig-
nificantly less severe hyperglycemia than KsJ mice (Figures 1A,B)
suggestive of partial recovery of function in existing β-cells and/or
spontaneous regeneration of new β-cells. Plasma insulin levels
were significantly higher in MIP-HSD1tg/+ than in KsJ mice at
day 3 and 10 (Figure 1C), consistent with their residual islet
insulin staining and further supporting an islet-specific β-cell
recovery (Figure 1D). Notably, circulating corticosterone levels
were markedly elevated by high STZ, but to a similar degree in KsJ
and MIP-HSD1tg/+ mice (nmol/l: KsJ vehicle: 131± 28, KsJ high
STZ: 535± 155, MIP-HSD1tg/+ vehicle: 138± 45 MIP-HSD1tg/+
high STZ: 683± 125, no significant effect of genotype), support-
ing a role for local β-cell GC regeneration as the underlying driver
of genotype-specific effects.
MIP-HSD1tg/+ MICE MAINTAIN HIGHER β-CELL MASS AND
REPLICATIVE CAPACITY AFTER STZ
The remarkable resilience of MIP-HSD1tg/+ β-cells against high-
dose STZ could be due to higher β-cell survival or increased
spontaneous β-cell regeneration. Of note, there was low and
comparable β-cell proliferation (~2% of total islet cell number
double-positive for the proliferation marker Ki67 and the β-cell
marker PDX1) in vehicle-treated KsJ and MIP-HSD1tg/+ mice
(Figure 2A, left lane and quantification Figure 2B). Islet PDX1-
positive β-cell number was severely reduced by day 3 and contin-
ued to fall by day 10 to undetectable levels in KsJ mice treated
with STZ. Replicating Ki67 single-positive cells in islets of STZ-
treated KsJ mice are likely infiltrating immune cells. Ki67/PDX1
double-positive cells were undetectable in KsJ islets indicating a
complete loss of β-cell replicative capacity (Figure 2A, upper row,
middle, and right lane and quantification, Figure 2B). Despite
a marked reduction in PDX1-positive cells, a substantial β-cell
number remained in STZ-treated MIP-HSD1tg/+ islets, although
the comparable hyperglycemia between genotypes from day 2
to 3 indicates these β-cells underwent a period of initial secre-
tory dysfunction (Figure 1). MIP-HSD1tg/+ mice also maintained
their Ki67/PDX1 double-positive cell number in their remain-
ing islets (Figure 2A bottom row and quantification Figure 2B)
suggesting that their β-cell replicative capacity is maintained
after STZ. This could not be accounted for by β-cell neogene-
sis from potential progenitor cell types, as assessed with SOX9
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FIGURE 1 | MIP-HSD1tg/+ mice exhibit episodic improvement in
hyperglycemia and higher islet insulin production after high-dose
STZ treatment. Twelve-week-old mice were given a single i.p. injection
of STZ (180 mg/kg/bodyweight) or citrate buffer as vehicle. (A) Daily
blood glucose in littermate vehicle-injected KsJ mice (•, n=5) and
MIP-HSD1tg/+ mice (◦, n=7) or after STZ injection in KsJ mice (, n=8)
and MIP-HSD1tg/+ mice (, n=12). Values represent mean±SEM,
differences were analyzed by one-way ANOVA, Newman–Keuls test,
*P <0.05 and **P <0.01 for MIP-HSD1tg/+ STZ vs. KsJ STZ. (B) Area
under the curve of overall blood glucose levels in littermate KsJ mice
(white bars) and MIP-HSD1tg/+ mice (black bars). ***P <0.001 for STZ
vs. vehicle, **P <0.01 for MIP-HSD1tg/+ STZ vs. KsJ STZ. (C) Plasma
insulin at day 0 (before injection) and days 3 and 10 post-STZ injection in
littermate KsJ mice (white bars) and MIP-HSD1tg/+ mice (black bars).
**P <0.01 and ***P <0.001 day 3 and 10 vs. day 0. The decrease in
plasma insulin was less severe in transgenic mice, ††P <0.01 for day 3
MIP-HSD1tg/+ STZ vs. day 3 KsJ STZ; ##P <0.01 for day 10 MIP-HSD1tg/+
STZ vs. day 10 KsJ STZ. (D) Insulin expression shown by
immunohistochemical staining of paraffin-fixed pancreata from KsJ
littermate (upper row) and MIP-HSD1tg/+ (lower row) mice after vehicle
treatment (Veh, left lane) and 3 (middle lane) or 10 days post-STZ
treatment (right lane). Bars=50µm magnification ×400.
and NEUROG3 (17, 18) immunostaining that did not differ
by genotype 3 or 10 days after STZ (Figures S1 and S2 in Sup-
plementary Material). Apoptosis was not detected in islets of
either genotype by a number of methods suggesting that this
process does not account for the differences between the genotypes
under these experimental conditions (Figure S3 in Supplementary
Material).
MIP-HSD1tg/+ ISLETS HAVE REDUCED MACROPHAGE AND INCREASED
T REGULATORY CELL INFILTRATION AFTER STZ
Inflammatory macrophage infiltration is an early event in autoim-
mune (2) and STZ-induced islet damage (19). MIP-HSD1tg/+
islets had fewer (~40%) infiltrated macrophages, as assessed by
the macrophage marker Mac-2, compared to KsJ controls at 3 and
10 days after the single high-dose STZ injection (Figure 3A and
quantification, Figure 3B).
T regulatory cells (Treg; FOXP3+ cells) mediate inflamma-
tory resolution and retard the progression of diabetes (20). Treg
cell numbers increased modestly (twofold) in both normal KsJ
and MIP-HSD1tg/+ islets/peri-islet area 3 days post-STZ. Treg
cell numbers continued to increase significantly only in MIP-
HSD1tg/+ islets by day 10 post-STZ (Figure 3C, and quantification
Figure 3D).
MIP-HSD1tg/+ MICE RESIST MULTIPLE LOW-DOSE STZ-INDUCED
HYPERGLYCEMIA
To test responses to a more subtle diabetic insult that recapit-
ulates some of the inflammatory and autoimmune aspects of
type 1 diabetes (21, 22), a low-dose of STZ (40 mg/kg/BW) was
administered for five consecutive days. KsJ mice showed signifi-
cant hyperglycemia from day 4 that reached a modestly diabetic
plateau by day 12 (Figure 4A), had reduced islet insulin staining
(Figure 4B) and increased islet macrophage numbers, whereas
MIP-HSD1tg/+ mice maintained normal glycemia and pancre-
atic morphology and displayed abrogated macrophage infiltration
(Figure 4C, and quantification, Figure 4D).
β-CELL 11β-HSD1 ACTIVITY CURTAILS ISLET STZ-INDUCED NITRIC
OXIDE PRODUCTION
Inflammatory mediators induce production of nitric oxide (NO)
that causes β-cell destruction and acts as an important chemoat-
tractant for macrophages (1, 3, 4). STZ can induce inflam-
matory pathways and islet damage in part by generating NO
(23). Incubation of normal KsJ islets with STZ stimulated NO
production (Figure 5A, white bars) and caused islet disinte-
gration (Figure 5C, middle lane, top row). The STZ-induced
rise in NO and islet damage was attenuated by the iNOS
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FIGURE 2 | MIP-HSD1tg/+ mice exhibit enhanced β-cell survival and
maintained replicative capacity after STZ treatment. (A) Representative
immunofluorescence images of paraffin-fixed pancreata co-stained with
rabbit anti-Ki67 (green), rabbit anti-PDX1 (red), and DAPI (blue) from KsJ
littermate (upper row), MIP-HSD1tg/+ (lower row) mice after vehicle treatment
(Veh, left lane), 3 (middle lane) and 10 days post-STZ treatment (right lane).
Arrows indicate double-positive stained cells, magnification ×400. (B) PDX1
and Ki67 positive cells were counted within the islets as defined
morphologically by the islet capsule boundary using Image J software.
Proliferating β-cells were measured as a ratio of PDX1, Ki67 double-positive
cells over total PDX1-positive cells. Ki67 and PDX1 double-positive staining
was undetectable (nd) in KsJ mice 3 and 10 days post-STZ treatment. Values
represented mean±SEM, differences were analyzed by one-way ANOVA,
Newman–Keuls test (n=6–12).
FIGURE 3 | MIP-HSD1tg/+ mice have reduced islet macrophage infiltration
and increasedT regulatory cell numbers after STZ administration.
(A) Immunohistochemical staining for Mac-2 with (B) quantification and
(C) FOXP3 immunohistochemical staining with (D) quantification.
(A,C) Pancreata from KsJ littermate (upper rows), MIP-HSD1tg/+ (lower rows)
mice after vehicle (left lane) or 3 (middle lane) and 10 days (right lane) post-STZ
treatment were paraffin-fixed and sectioned. (C,D) Mac-2 and FOXP3 positive
cells per islet area were quantified using Zeiss (KS300 3.0) software. Values
represent mean±SEM. Differences were analyzed by one-way ANOVA and
Newman–Keuls test, *P <0.05 and ***P <0.001 for STZ vs. Veh; *P <0.05
and **P <0.01 for MIP-HSD1tg/+ vs. KsJ control; §P <0.05 and §§§P <0.001
STZ D10 vs. STZ D3 (n=6–10). Bars=50µm, magnification ×400.
inhibitor, L-NAME (Figures 5A,C, right lane). NO production
was suppressed after STZ treatment of MIP-HSD1tg/+ islets
(Figure 5B, black bars) and islet disintegration was attenuated
(Figure 5C, middle lane, bottom row). The specific 11beta-HSD1
inhibitor UE2316 (14) reversed suppression of NO found in MIP-
HSD1tg/+ islets in the presence of the 11beta-HSD1 substrate
11-dehydrocorticosterone, confirming that β-cell 11beta-HSD1
activity inhibits NO production.
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FIGURE 4 | MIP-HSD1tg/+ mice completely resist hyperglycemia
induced by multiple low-dose injection of STZ. Twelve-week-old mice
were injected i.p. either with sodium citrate vehicle or STZ (40 mg/kg/body
weight) for five consecutive days. (A) Blood glucose levels measured
immediately before injections (day 0) and day 4, 8, 12, and 15 after vehicle
injection in littermate KsJ mice (•, n=5) or MIP-HSD1tg/+ mice (, n=7)
and after STZ injection in littermate KsJ mice (◦, n=8) or MIP-HSD1tg/+
mice (, n=12). Blood glucose level in MIP-HSD1tg/+ STZ-treated mice
was significantly elevated only KsJ STZ-treated mice. Values represented
mean±SEM. Differences were analyzed by one-way ANOVA,
Newman–Keuls test, ***P <0.001 for KsJ STZ vs. KsJ Veh; *P <0.05 and
**P <0.01, † † †P ≤0.001 for MIP-HSD1tg/+ STZ vs. KsJ STZ.
(B) Preservation of islet structure in MIP-HSD1tg/+ shown by insulin
staining of paraffin-fixed pancreata from KsJ mice (upper row) and
MIP-HSD1tg/+ mice (bottom row) 10 days after the end of vehicle (Veh, left
lane) or STZ (right lane) treatment. Scale=400µm magnification ×50.
(C) Reduced macrophage infiltration in MIP-HSD1tg/+ shown by Mac-2
staining of paraffin-fixed pancreata from KsJ mice (upper row) and
MIP-HSD1tg/+ mice (bottom row) 10 days after the end of vehicle (Veh, left
lane) or STZ (right lane) treatment. Bars=50µm, magnification ×400.
(D) Quantitation of Mac-2 positive cells per islet area using Zeiss (KS300,
3.0) software. Values represent mean±SEM, differences were analyzed
by one-way ANOVA, Newman–Keuls test, ***P <0.001 for STZ vs. Veh;
***P <0.001 for MIP-HSD1tg/+ STZ vs. KsJ STZ (n=5–10).
DISCUSSION
Modest elevation of 11beta-HSD1 activity in β-cells (14) has con-
ferred improved β-cell survival and a sustained capacity for spon-
taneous β-cell regeneration in the context of severe inflammatory
β-cell destruction. Although the protection against hyperglycemia
is modest across the short-time course of the present studies,
the continued survival and replenishment of functional β-cells
after high-dose STZ points to a remarkable and unexpectedly
effective protective role for local GC regeneration. Hyperglycemia
induced by multiple low-dose STZ, a regimen that invokes some
of the autoimmune and inflammatory processes (21, 22, 24)
to that found in type 1 diabetes, was completely prevented in
MIP-HSD1tg/+ mice.
The protective effect of elevated β-cell 11beta-HSD1 involves
both increased β-cell survival and maintained β-cell replicative
potential. Improved MIP-HSD1tg/+ islet survival is mediated by
GC-mediated suppression of pro-inflammatory NO production
(3, 4), an effect of GCs also found in the vasculature (25). Increased
expression of heat shock and other cellular stress–resistance path-
ways in MIP-HSD1tg/+ islets (14) is consistent with their aug-
mented survival, and may counteract triggering of more aggressive
inflammatory responses after β-cell insult.
Under normal physiological conditions, β-cell mass is main-
tained through slow rates of renewal and turnover (26). Hyper-
glycemia can prompt islet mass compensation predominantly
through hypertrophy of existing β-cells (27), β-cell prolifera-
tion (26), and neogenesis from progenitors, at least in pancre-
atic injury models (18). However, we found no evidence for
altered ductal (SOX9) or islet endocrine (NEUROG3) progeni-
tor cells as the basis of maintained β-cell mass in STZ-treated
MIP-HSD1tg/+ mice, in agreement with recent findings that β-
cell neogenesis does not come from ductal cell progenitors in
the adult pancreas (17). Thus, altered GC regeneration selectively
impacts upon β-cell replication in the STZ-injured adult pancreas.
Moreover, MIP-HSD1tg/+ islets exhibit a hyper-functionality asso-
ciated with increased Cdkn1a (P21) expression suggesting acceler-
ated functional maturation of MIP-HSD1 β-cells (14), consistent
with the role of GCs in terminal differentiation. Newly gener-
ated MIP-HSD1 β-cells likely achieve functionality more rapidly
than normal β-cells. In support of this notion, overexpression of
the pro-differentiation factor P21 in β-cells promotes resistance
to high-dose STZ by increasing progenitor differentiation (28).
Notably, apoptosis was undetectable in STZ-treated KsJ mouse
islets and pancreas, despite a strong signal in our positive con-
trol spleen tissue (Figure S3B in Supplementary Material). It
cannot be ruled out that our time points missed a significant
incidence of apoptosis, as noted by others (29) or that rapid
turnover of apoptotic cells markers [within minutes; (30)] may
have caused the signal to fall below our limit of detection. Exper-
imental designs more suited to inducing β-cell apoptosis will be
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FIGURE 5 | Isolated MIP-HSD1tg/+ islets show attenuated induction of
nitric oxide production and resistance to disintegration in culture after
STZ challenge. Islets from 12-week-old mice were isolated and incubated
in vitro with vehicle or STZ (10 mmol/l) with or without the nitric oxide
synthase inhibitor L-NAME (5 mmol/l) in the presence of 2 nmol/l
11-dehydrocorticosterone 11beta-HSD1 substrate for 72 h. (A) Analysis of
nitric oxide (NO) production in media after 72 h incubation with vehicle (−),
STZ or STZ+L-NAME from islets from KsJ (white bars) or MIP-HSD1tg/+
mice (black bars). Values represent mean±SEM. Differences were
analyzed by one-way ANOVA, Newman–Keuls test, ***P <0.001 for STZ
vs. Veh; †††P <0.001 for MIP-HSD1tg/+ STZ vs. KsJ STZ, §§P <0.01
STZ+L-NAME vs. STZ (n=6). (B) NO production in media of isolated islets
from MIP-HSD1tg/+ mice treated with STZ with or without 11beta-HSD1
inhibitor UE2316 (1µmol/l) for 72 h. Values represent mean±SEM,
differences analyzed by one-way ANOVA, Newman–Keuls test,
***P <0.001 for STZ vs. Veh; **P <0.01 for STZ+UE2316 vs. STZ (n=6).
(C) Representative light microscopy images of islets from KsJ (upper row)
and MIP-HSD1tg/+ mice (lower row) incubated with vehicle (left lane), with
STZ (middle lane), or with STZ+L-NAME (right lane). Magnification ×400.
needed to determine the contribution of altered β-cell GCs to this
process.
Macrophage infiltration in diabetic islets is an early event (1–4).
Depletion (19) or inactivation (2) of macrophages prevents the
progression of type 1 diabetes, highlighting the importance of the
inflammatory mechanism per se in islet destruction. Reduction
of macrophage infiltration in MIP-HSD1tg/+ islets is consistent
with a reduced inflammatory insult that will work, at least in
part, through longer-term curtailment of cytokine-mediated NO
generation long after the STZ has been metabolized. GCs sup-
press a number of distinct pro-inflammatory signaling pathways
that will also contribute to overall improvement in islet func-
tion (5). The higher Treg cell influx into MIP-HSD1tg/+ pancreas
is consistent with increased islet GC levels influencing infiltrat-
ing macrophages to signal for resolution of inflammation (31).
Increased T regulatory cell numbers also suggests that a greater
suppression of pathogenic pro-inflammatory CD8+ Th1 cells and,
intriguingly, may indicate enhanced suppression of self-antigens
(32) and autoimmune responses over a longer time frame, which
can only be addressed in future work in models such as the NOD
mouse strain and in transplant models.
Of clinical significance, new technological advances in biohy-
bridβ-cell transplant methods have achieved improvement of graft
β-cell survival using slow-release of local corticosteroids, report-
edly as a consequence of local immunosuppression (12). Our
previous (14) and current data suggest that the secretory func-
tion and survival of encapsulated or transplanted human β-cells,
which appear to express 11beta-HSD1 (33) could be potentially
augmented through pre-treatment or local release of low-dose
cortisone, thus, avoiding the deleterious effects of high dose or
systemic GC administration that has hitherto precluded their use
in this context.
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